According to above evidence, CARD16 is increased in malignant glioma and functions as a tumor promoter in glioma through enhancing phosphorylation and ubiquitination of FOXO1, and additionally limiting TRAIL-induced apoptosis. Here, FOXO1 is linked to central nervous system cancer.